Danaher Corporation (DHR)

NYSE: DHR · IEX Real-Time Price · USD
264.38
+1.63 (0.62%)
At close: Jan 31, 2023, 4:04 PM
264.30
-0.08 (-0.03%)
Pre-market: Feb 1, 2023, 6:00 AM EST
0.62%
Market Cap 192.55B
Revenue (ttm) 31.25B
Net Income (ttm) 6.64B
Shares Out 728.30M
EPS (ttm) 9.05
PE Ratio 29.21
Forward PE 25.91
Dividend $1.00 (0.38%)
Ex-Dividend Date Dec 29, 2022
Volume 2,514,146
Open 263.02
Previous Close 262.75
Day's Range 260.42 - 265.18
52-Week Range 233.71 - 303.82
Beta 0.82
Analysts Buy
Price Target 311.15 (+17.69%)
Earnings Date Jan 24, 2023

About DHR

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filt... [Read more]

Sector Healthcare
Founded 1969
Employees 78,000
Stock Exchange NYSE
Ticker Symbol DHR
Full Company Profile

Financial Performance

In 2021, Danaher's revenue was $29.45 billion, an increase of 32.17% compared to the previous year's $22.28 billion. Earnings were $6.27 billion, an increase of 78.60%.

Financial Statements

Analyst Forecast

According to 30 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $311.15, which is an increase of 17.69% from the latest price.

Price Target
$311.15
(17.69% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Danaher: A Future-Focused Spinoff Value Play

In September 2022, Danaher Corp. ( DHR , Financial) announced its intention to spin off its environmental and applied solutions segment into a separate publicly traded business in the fourth quarter o...

1 day ago - GuruFocus

Danaher (DHR) Q4 Earnings & Revenues Beat, Increase Y/Y

Danaher's (DHR) Q4 results benefit from strong segmental performances and organic sales growth.

1 week ago - Zacks Investment Research

Danaher Hit After Cutting Covid-Related Revenue From Growth Reports

The medical company's fourth-quarter earnings beat expectations, but analysts say investors are paying attention to other elements of the report.

1 week ago - Barrons

Danaher (DHR) Tops Q4 Earnings and Revenue Estimates

Danaher (DHR) delivered earnings and revenue surprises of 16.67% and 9.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Danaher Reports Fourth Quarter and Full Year 2022 Results

WASHINGTON , Jan. 24, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2022.  All results in this release reflect only ...

1 week ago - PRNewsWire

HTHIY vs. DHR: Which Stock Is the Better Value Option?

HTHIY vs. DHR: Which Stock Is the Better Value Option?

1 week ago - Zacks Investment Research

Will Cost Headwinds Dampen Danaher's (DHR) Q4 Earnings?

High raw material costs and supply-chain disruptions are likely to have hurt Danaher's (DHR) Q4 earnings. However, the top line is likely to have benefited from an expected increase in revenues at the...

2 weeks ago - Zacks Investment Research

Analysts Estimate Danaher (DHR) to Report a Decline in Earnings: What to Look Out for

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

3 Stocks Ron Baron and Daniel Loeb Agree On

Ron Baron (Trades, Portfolio) and Daniel Loeb (Trades, Portfolio) are two gurus that follow very different investing styles. While both focus on the long term, Baron's Baron Funds aims to invest in va...

Other symbols: TTWOUNH
2 weeks ago - GuruFocus

Here's Why Hold Strategy is Apt for Danaher (DHR) Stock Now

Strength across the Life Sciences segment, inorganic activities and DBS initiatives bode well for Danaher's (DHR) growth. Shareholder-friendly policies add to the stock's appeal.

2 weeks ago - Zacks Investment Research

Danaher (DHR) Provides Improved Q4 Core Revenue Growth Guidance

Benefiting from strong growth in Cepheid's molecular diagnostics among other factors, Danaher (DHR) improves its adjusted core revenue growth guidance for the fourth quarter of 2022.

3 weeks ago - Zacks Investment Research

Danaher sees Q4 sales increasing in ‘low-single-digit percent range'

Danaher Corp. DHR, +1.01% on Monday said it expected fourth-quarter sales to rise in the “low-single-digit percent range,” despite what executives said was a “challenging environment” for the maker of...

3 weeks ago - Market Watch

Danaher CEO to Comment on Financial Performance

WASHINGTON , Jan. 9, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compan...

3 weeks ago - PRNewsWire

Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer

OTTAWA, Canada--(BUSINESS WIRE)--Virica Biotech Inc. (“Virica”), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be j...

3 weeks ago - Business Wire

Danaher to Present at J.P. Morgan Healthcare Conference

WASHINGTON , Jan. 3, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.

1 month ago - PRNewsWire

Why Danaher (DHR) Could Beat Earnings Estimates Again

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago - Zacks Investment Research

How to Find Strong Multi-Sector Conglomerates Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

1 month ago - Zacks Investment Research

Final Trades: American Water, Boeing, Danaher & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: AWKBAABC
1 month ago - CNBC Television

Danaher Schedules Fourth Quarter 2022 Earnings Conference Call

WASHINGTON , Dec. 27, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2022 on Tuesday, January 24, 202...

1 month ago - PRNewsWire

Grade My Trade: SMH & DHR

The ‘Halftime Report' investment committee, Shannon Saccocia, Sarat Sethi, Joe Terranova and Jim Lebenthal, weigh in on the Danaher and semis trade.

Other symbols: SMH
1 month ago - CNBC Television

Jim Cramer recommends these 5 healthcare stocks in 2023

Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks.

Other symbols: EWHUMPFEUNH
1 month ago - CNBC

Danaher (DHR) Up 14% in 6 Months: What's Driving the Stock?

Danaher (DHR) gains from strength across its core Life Sciences segment, benefits from the DBS initiatives and acquired assets. The company's efforts to add shareholder value hold promise.

1 month ago - Zacks Investment Research

Danaher Announces Quarterly Dividends

WASHINGTON , Dec. 6, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.25 per share of its common st...

2 months ago - PRNewsWire

Danaher to Present at Evercore ISI HealthCONx Conference

WASHINGTON , Nov. 22, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf...

2 months ago - PRNewsWire

Danaher (DHR) Just Reclaimed the 200-Day Moving Average

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

2 months ago - Zacks Investment Research